Neuronetics (STIM) Scheduled to Post Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Neuronetics has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The firm had revenue of $16.45 million during the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative return on equity of 109.00% and a negative net margin of 45.06%. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Up 8.3 %

Neuronetics stock opened at $1.17 on Friday. The business has a fifty day moving average price of $0.90 and a 200-day moving average price of $1.60. The company has a debt-to-equity ratio of 2.38, a current ratio of 2.58 and a quick ratio of 2.37. Neuronetics has a 1-year low of $0.66 and a 1-year high of $5.07. The stock has a market capitalization of $35.46 million, a price-to-earnings ratio of -1.04 and a beta of 2.21.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on STIM shares. William Blair reissued a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th. JMP Securities decreased their target price on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. Finally, Canaccord Genuity Group reduced their target price on Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Insider Buying and Selling at Neuronetics

In other news, Director Robert Cascella purchased 100,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were bought at an average cost of $0.75 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the director now directly owns 453,098 shares of the company’s stock, valued at approximately $339,823.50. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 211,776 shares of company stock worth $175,170 over the last quarter. 9.80% of the stock is currently owned by company insiders.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.